CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced that Andrew J. Hirsch has joined the company as its Chief Financial Officer. Mr. Hirsch brings nearly twenty years of financial leadership and strategic management experience.
